We are live on ! Find out more
FULC icon

Fulcrum Therapeutics

110 hedge funds and large institutions have $648M invested in Fulcrum Therapeutics in 2021 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 41 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more call options, than puts

Call options by funds: $2.24M | Put options by funds: $1.22M

78% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 23

42% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 24

9% more funds holding

Funds holding: 101110 (+9)

1.65% more ownership

Funds ownership: 92.98%94.63% (+1.6%)

36% less capital invested

Capital invested by funds: $1.01B → $648M (-$362M)

60% less funds holding in top 10

Funds holding in top 10: 52 (-3)

Holders
110
Holders Change
+9
Holders Change %
+8.91%
% of All Funds
1.69%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
34
Increased
41
Reduced
23
Closed
24
Calls
$2.24M
Puts
$1.22M
Net Calls
+$1.02M
Net Calls Change
+$1.92M
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
51
Cinctive Capital Management
New York
$639K +$715K +36,120 New
SSA
52
Schonfeld Strategic Advisors
New York
$628K -$923K -46,600 -57%
CTB
53
Country Trust Bank
Illinois
$622K -$42.7K -2,155 -6%
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$561K +$29.9K +1,508 +5%
Jane Street
55
Jane Street
New York
$552K -$370K -18,703 -37%
Prudential Financial
56
Prudential Financial
New Jersey
$509K +$570K +28,770 New
PAM
57
Panagora Asset Management
Massachusetts
$505K +$2.63K +133 +0.5%
AA
58
AlphaCentric Advisors
Puerto Rico
$504K +$565K +28,500 New
Bank of America
59
Bank of America
North Carolina
$495K +$406K +20,496 +274%
Deutsche Bank
60
Deutsche Bank
Germany
$484K -$182K -9,208 -25%
BM
61
Brandywine Managers
Delaware
$447K +$96.9K +4,892 +24%
CSS
62
Cubist Systematic Strategies
Connecticut
$441K -$110K -5,574 -18%
UMC
63
UNC Management Company
North Carolina
$419K +$470K +23,708 New
Wells Fargo
64
Wells Fargo
California
$403K +$336K +16,959 +289%
AllianceBernstein
65
AllianceBernstein
Tennessee
$382K +$99K +5,000 +30%
E
66
Ergoteles
New York
$379K +$424K +21,400 New
AGM
67
Alpine Global Management
New York
$370K +$414K +20,905 New
OMC
68
Old Mission Capital
Illinois
$366K +$409K +20,670 New
Squarepoint
69
Squarepoint
New York
$340K +$381K +19,229 New
CS
70
Credit Suisse
Switzerland
$332K +$371K +18,752 New
New York State Common Retirement Fund
71
New York State Common Retirement Fund
New York
$329K -$258 -13 -0.1%
Legal & General Group
72
Legal & General Group
United Kingdom
$323K +$319K +16,129 +758%
Mitsubishi UFJ Asset Management
73
Mitsubishi UFJ Asset Management
Japan
$298K +$332K +16,742 New
GTCM
74
Gyon Technologies Capital Management
New Jersey
$275K +$308K +15,534 New
AIG
75
American International Group
New York
$258K +$456 +23 +0.2%

FULC Hedge Fund Activity: Q4 2021 in Review

110 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2021, worth a combined $648M — down 36% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new FULC positions and 24 closed out — a net gain of 10 holders — while 41 added to existing stakes and 23 trimmed.

The largest buyer was Holocene Advisors, opening a new position worth an estimated $17.1M. The largest seller was Cowen and Company, exiting entirely with an estimated $44M sold.

  • 110 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2021, up from 101 in Q3 2021.
  • Funds reported $648M of Fulcrum Therapeutics stock for Q4 2021, down 36% quarter-over-quarter.
  • 34 funds opened new Fulcrum Therapeutics positions in Q4 2021 and 24 closed out, a net change of +10 holders.
  • The largest Fulcrum Therapeutics buyer in Q4 2021 was Holocene Advisors, an estimated $17.1M added.
  • The largest Fulcrum Therapeutics seller in Q4 2021 was Cowen and Company, an estimated $44M sold.

Based on aggregated 13F filings for Q4 2021.